Replies to post #96140 on Biotech Values

[DewDiligence]

BPAX:

Between this [sleazy] PR and the decision to spend precious resources on the GVAX program, coupled with the fact that so much of the value of the company is riding on a Phase-3 binary event for LibiGel, I'm less inclined to think of BPAX as worthy of investment and have pretty much dropped the stock from my watch list.

Not to mention that they buried the increased FDA-mandated size of the LibiGel safety trials in an SEC filing without even issuing a PR (#msg-50289819).

When you consider that BPAX chose not to PR the consequential change in the LibiGel safety trials, but they did choose to PR the blatant pump re the unaffiliated NVS program, it does not paint a pretty picture. With each passing day, Stephen Simes is acting more and more like a used-car salesman and BPAX is looking more and more like a sucker play.